Literature DB >> 30738781

Combination therapies in prostate cancer: proceed with caution.

Daniel E Spratt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30738781     DOI： 10.1016/S1470-2045(18)30929-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223.

Authors:  Orazio Caffo; Viviana Frantellizzi; Marcello Tucci; Luca Galli; Fabio Monari; Sergio Baldari; Cristina Masini; Roberto Bortolus; Gaetano Facchini; Pierpaolo Alongi; Stefania Agostini; Clizia Zichi; Elisa Biasco; Stefano Fanti; Salvatore Pignata; Angelina Filice; Eugenio Borsatti; Sabrina Rossetti; Massimiliano Spada; Enrico Cortesi; Giuseppe De Vincentis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-05       Impact factor: 9.236

Review 2.  Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.

Authors:  Antonella Argentiero; Antonio Giovanni Solimando; Oronzo Brunetti; Angela Calabrese; Francesco Pantano; Michele Iuliani; Daniele Santini; Nicola Silvestris; Angelo Vacca
Journal:  Cancers (Basel)       Date:  2019-08-29       Impact factor: 6.639

Review 3.  Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review.

Authors:  Bartosz Malinowski; Michał Wiciński; Nikola Musiała; Ilona Osowska; Mateusz Szostak
Journal:  Diagnostics (Basel)       Date:  2019-10-25

4.  Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients.

Authors:  Yasuhide Miyoshi; Masato Yasui; Sohgo Ttsutsumi; Takashi Kawahara; Ko-Ichi Uemura; Naruhiko Hayashi; Masahiro Nozawa; Kazuhiro Yoshimura; Hiroji Uemura; Hirotsugu Uemura
Journal:  BJUI Compass       Date:  2020-09-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.